| ²é¿´: 2580 | »Ø¸´: 6 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
[½»Á÷]
¼±£¡°ïæ·ÒëһЩ·Ö×ÓÉúÎïѧ·½ÃæµÄÓ¢ÎÄÎÄÏ×¶ÎÂä
|
|||
|
Based on the facts that purified ENTPD5 is unable to hydrolyze ATP directly and the assay also contained S-100 from PTEN heterozygous MEFs, we realized that there must be more factors in the S-100, which are also required to hydrolyze ATP to AMP. These factors presented in cells regardless of their PTEN status. For example, when we added purified, recombinant ENTPD5 and UMP to the dialyzed S-100 from large-scale cultured HeLa cells, the ATP-to-AMP hydrolysis was reconstituted (Figure 4A, lanes 1¨C6). This observation made purification of these factors easier because HeLa cells can be grown in large quantity insuspension. To identify these factors, we fractionated HeLa cell S-100, using a Q Sepharose column, and collected both the flowthrough (Q-FL) and column-bound fractions eluted with 300 mM NaCl (Q-30). Neither fraction alone was able to hydrolyze ATP to AMP, although the Q-30 fraction, when ENTPD5 and UMP were present, hydrolyzed ATP to ADP (Figure 4A, lanes 13 and 14). When both the Q-FL and Q-30 fractions were included, the ATP-to-AMP activity was fully reconstituted (Figure 4A, lane 18). We purified the activity present in the Q-30 fraction. The activity present in the Q-30 fraction was purified by subjecting HeLa S-100 onto four sequential column chromatographic steps and finally onto a Mini Q column (Figure 4B, left). The activity was eluted from this column with a linear salt gradient from 40 to 120 mM NaCl, and fractions eluted from the column were assayed in the presence of recombinant ENTPD5, UMP, and the Q-FL fraction (Figure 4B, right-bottom). A peak of activity was observed at fractions 8¨C10. The same fractions were subjected to SDS-PAGE followed by silver staining, and two protein bands close to 37 and 20 kDa markers correlated perfectly with activity (Figure 4B, right-top). Both bands were identified by mass spectrometry as human UMP/CMP kinase-1 (CMPK1).The identification of UMP/CMP kinase in the Q-30 fraction shed light on why UMP is a cofactor for the ATPase activity and how ENTPD5 plus this enzyme generates ADP from ATP. In this reaction, UMP is phosphorylated into UDP by CMPK1 and ATP, generating ADP. UDP is subsequently hydrolyzed by ENTPD5 to UMP, completing the cycle with net conversion of ATP to ADP. With this knowledge, wethen made an educated guess that the third protein factor present in the Q flowthrough fraction should be an adenylate kinase, which converts two ADP into one ATP and AMP, causing the ATP-to-AMP conversion seen in PTEN null cell extracts. To confirm this, we took theQflowthrough fraction and subjected it to a gel-filtration column and collected the fractions eluted from the column to assay for ATP-to-AMP hydrolysis in the presence of UMP, purified recombinant ENTPD5, and the Q-30 fraction that contains CMPK1. An ATP-to-AMP activity peak centered at fractions 17 and 18 was observed (Figure 4C, top). When these factions were subjected to western blotting analysis using an antibody against adenylate kinase-1 (AK1), the detected western blotting band correlated perfectly with the activity peak (Figure 4C, bottom). The correlation was maintained with additional chromatographic steps (data not shown). We subsequently generated recombinant CMPK1 and AK1 in bacteria and purified them to homogeneity (Figure 4D, lanes 9 and 12). Purified recombinant ENTPD5 expressed in insect cells runs as a triplet on an SDS-PAGE gel that could be shifted down to a doublet after treatment by PNGase F, indicating that ENTPD-5 is glycosylated (Figure 4D, lanes 10 and 11). These purified recombinant proteins allowed us to reconstitute the ATP-to-AMP hydrolysis cycle. Only when all three enzymes and UMP were present, efficient ATP-to-AMP conversion was observed (Figure 4D, lanes 1¨C8). |
» ²ÂÄãϲ»¶
¸´ÊÔµ÷¼Á
ÒѾÓÐ14È˻ظ´
»¯Ñ§070300 Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸085502£¬267·ÖÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
277Çóµ÷¼Á
ÒѾÓÐ22È˻ظ´
268·Ö085602»¯Ñ§¹¤³Ìµ÷¼Á
ÒѾÓÐ29È˻ظ´
ÉúÎïѧ308Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸¹þ¹¤´ó 085600 277 12²Ä¿Æ»ùÇóµ÷¼Á
ÒѾÓÐ29È˻ظ´
2±¾£¬³õÊÔ303£¬0860Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
279ѧ˶ʳƷרҵÇóµ÷¼ÁԺУ
ÒѾÓÐ16È˻ظ´
²ÄÁϹ¤³Ì085601£¬270Çóµ÷¼Á
ÒѾÓÐ34È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
´óÁ¬´óѧ-ÁùÅÌˮʦ·¶Ñ§ÔºÁªºÏÅàÑøÑо¿Éú½ÓÊÕµ÷¼Á
+2/252
¡ï¡ï¾«Æ·¡ï¡ï0860ÉúÎïÓëÒ½Ò©»¹Óе÷¼ÁÖ¸±ê£¬×îºóµÄ»ú»á£¬¼ñ©Éϰ¶
+1/131
³¤½´óѧ»¯¹¤Ñ§Ôº»·¾³Ñ§Ë¶¡¢×¨Ë¶×îºóÒ»Åúµ÷¼Á£¨Àíѧ¡¢¹¤Ñ§¾ù¿É£¬ÏßÉÏÃæÊÔ£©
+1/89
½Î÷Àí¹¤´óѧ̼²ÄÁÏÓëÐÂÄÜÔ´¿ÎÌâ×éÕÐÊÕ2026Äêµ÷¼ÁÉú£¨Ñ§Ë¶Ë¶²©Á¬¶Á£©
+1/87
»¯Ñ§¡¢»¯Ñ§¹¤³Ì¡¢ÉúÎïÓëÒ½Ò©£¬Î¢ÉúÎïѧ¡¢ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧרҵµ÷¼Á
+1/41
²»ÄÜÀí½â
+1/28
»¯Ñ§¡¢»·¾³¹¤³Ì£¬Éϳµ¾Í×ß
+1/22
BÇøµ÷¼Á À¼Öݽ»Í¨´óѧ²ÄÁÏѧԺµ÷¼Á
+1/20
´óÁ¬´óѧ-¹óÖÝʡú̿½à¾»ÀûÓÃÖØµãʵÑéÊÒÁªºÏÅàÑøÑо¿Éú »¯Ñ§5ÈË+»·¾³¹¤³Ì7ÈË
+1/12
Ê¡ÖØµãʵÑéÊÒÕÐÊÕµ÷¼ÁÉú£¬º£ÑóÉúÎïרҵÃû¶î³ä×ã
+1/12
ÄÏ»ª´óѧ×ÊÔ´Óë»·¾³½ÓÊܵ÷¼Á£¬×¨ÒµÌØÉ«£º¡°ºË¡±»·±££¬Óлú»á½øÈëºËÏà¹ØÆóÒµ¹¤×÷¡£
+1/10
£¨Éϳµ¾Í×ߣ©µ÷¼Á»¯Ñ§-»·¾³ ¹óÖÝʡú̿½à¾»ÀûÓÃÖØµãʵÑéÊÒ
+1/10
¡ïÉϺ£¡ïÉϺ£¹¤³Ì¼¼Êõ´óѧ¡¤»·¾³Óë×ÊÔ´´´ÐÂÖÐÐÄ£¨ICER£©½ÓÊÕ»¯¹¤²ÄÁÏ»·¾³µÈѧ¿Æµ÷¼ÁÉú
+1/8
¡¾»ªÖпƼ¼´óѧ¡¿¡¾¹ÜÀíѧԺ¡¿¡¾ÎâÇ컪½ÌÊÚÍŶӡ¿¡¾ÕÐÊÕ2-3Ãû²©Ê¿ºó¡¿
+1/7
0854,0858µ÷¼ÁÕÐÉú
+1/5
¼ªÁÖ¹¤³Ì¼¼Êõʦ·¶Ñ§Ôº ½»²æÑ§¿ÆÑо¿Ôº£¨08/07£© ÕÐÊÕµ÷¼Á
+1/5
»ª±±Àí¹¤´óѧ¿óÒµ¹¤³Ì-¿óÎï¼Ó¹¤¹¤³Ì·½Ïò½ÓÊÕµ÷¼ÁÑо¿Éú
+1/5
Î÷ÄϿƼ¼´óѧ¹ú¼ÒÖØµãʵÑéÊÒÀîÀÏʦ¿ÎÌâ×é½ÓÊÕ²ÄÁÏ¡¢»¯Ñ§ºÍ»¯¹¤ÀàÑо¿Éúµ÷¼Á
+1/4
¸£½¨Àí¹¤´óѧ²ÄÁÏѧԺÕÐÊÕרҵ´úÂë08¿ªÍ·Ñ§ÊõÐÍ˶ʿÑо¿Éú
+1/4
´óÁ¬¹¤Òµ´óѧ·ÄÖ¯Óë²ÄÁϹ¤³ÌѧԺ³¬ÁÙ½çÁ÷Ìå¼¼Êõ¿ÎÌâ×é Ñо¿Éúµ÷¼Á
+1/4
foryever
ľ³æ (ÎÄ̳¾«Ó¢)
- ·ÒëEPI: 15
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ¹ó±ö: 0.038
- ½ð±Ò: 2698.8
- Ìû×Ó: 11281
- ÔÚÏß: 447.4Сʱ
- ³æºÅ: 700250
ǰÊÀ½ñÉú(½ð±Ò+5):ÅŰæÐÁ¿àÁË£¡£¡£¡ 2010-11-25 14:15:51
|
µÈ´ýÀϰåÖУ¬°ïÂ¥Ö÷ÅŸö°æ£¬·ÇÖÐÎĵ¥´ÊÊý£º600 Based on the facts that purified ENTPD5 is unable to hydrolyze ATP directly and the assay also contained S-100 from PTEN heterozygous MEFs, we realized that there must be more factors in the S-100, which are also required to hydrolyze ATP to AMP. These factors presented in cells regardless of their PTEN status. For example, when we added purified, recombinant ENTPD5 and UMP to the dialyzed S-100 from large-scale cultured HeLa cells, the ATP-to-AMP hydrolysis was reconstituted (Figure 4A, lanes 1¨C6). This observation made purification of these factors easier because HeLa cells can be grown in large quantity insuspension. To identify these factors, we fractionated HeLa cell S-100, using a Q Sepharose column, and collected both the flowthrough (Q-FL) and column-bound fractions eluted with 300 mM NaCl (Q-30). Neither fraction alone was able to hydrolyze ATP to AMP, although the Q-30 fraction, when ENTPD5 and UMP were present, hydrolyzed ATP to ADP (Figure 4A, lanes 13 and 14). When both the Q-FL and Q-30 fractions were included, the ATP-to-AMP activity was fully reconstituted (Figure 4A, lane 18). We purified the activity present in the Q-30 fraction. The activity present in the Q-30 fraction was purified by subjecting HeLa S-100 onto four sequential column chromatographic steps and finally onto a Mini Q column (Figure 4B, left). The activity was eluted from this column with a linear salt gradient from 40 to 120 mM NaCl, and fractions eluted from the column were assayed in the presence of recombinant ENTPD5, UMP, and the Q-FL fraction (Figure 4B, right-bottom). A peak of activity was observed at fractions 8¨C10. The same fractions were subjected to SDS-PAGE followed by silver staining, and two protein bands close to 37 and 20 kDa markers correlated perfectly with activity (Figure 4B, right-top). Both bands were identified by mass spectrometry as human UMP/CMP kinase-1 (CMPK1).The identification of UMP/CMP kinase in the Q-30 fraction shed light on why UMP is a cofactor for the ATPase activity and how ENTPD5 plus this enzyme generates ADP from ATP. In this reaction, UMP is phosphorylated into UDP by CMPK1 and ATP, generating ADP. UDP is subsequently hydrolyzed by ENTPD5 to UMP, completing the cycle with net conversion of ATP to ADP. With this knowledge, wethen made an educated guess that the third protein factor present in the Q flowthrough fraction should be an adenylate kinase, which converts two ADP into one ATP and AMP, causing the ATP-to-AMP conversion seen in PTEN null cell extracts. To confirm this, we took theQflowthrough fraction and subjected it to a gel-filtration column and collected the fractions eluted from the column to assay for ATP-to-AMP hydrolysis in the presence of UMP, purified recombinant ENTPD5, and the Q-30 fraction that contains CMPK1. An ATP-to-AMP activity peak centered at fractions 17 and 18 was observed (Figure 4C, top). When these factions were subjected to western blotting analysis using an antibody against adenylate kinase-1 (AK1), the detected western blotting band correlated perfectly with the activity peak (Figure 4C, bottom). The correlation was maintained with additional chromatographic steps (data not shown). We subsequently generated recombinant CMPK1 and AK1 in bacteria and purified them to homogeneity (Figure 4D, lanes 9 and 12). Purified recombinant ENTPD5 expressed in insect cells runs as a triplet on an SDS-PAGE gel that could be shifted down to a doublet after treatment by PNGase F, indicating that ENTPD-5 is glycosylated (Figure 4D, lanes 10 and 11). These purified recombinant proteins allowed us to reconstitute the ATP-to-AMP hydrolysis cycle. Only when all three enzymes and UMP were present, efficient ATP-to-AMP conversion was observed (Figure 4D, lanes 1¨C8). |
2Â¥2010-11-23 09:35:56
ringzhu
ľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 24
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ¹ó±ö: 1.318
- ½ð±Ò: 1370.6
- Ìû×Ó: 4511
- ÔÚÏß: 703.5Сʱ
- ³æºÅ: 825134
3Â¥2010-11-23 16:54:30
foryever
ľ³æ (ÎÄ̳¾«Ó¢)
- ·ÒëEPI: 15
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ¹ó±ö: 0.038
- ½ð±Ò: 2698.8
- Ìû×Ó: 11281
- ÔÚÏß: 447.4Сʱ
- ³æºÅ: 700250
4Â¥2010-11-23 18:19:51
ringzhu
ľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 24
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ¹ó±ö: 1.318
- ½ð±Ò: 1370.6
- Ìû×Ó: 4511
- ÔÚÏß: 703.5Сʱ
- ³æºÅ: 825134
5Â¥2010-11-23 18:35:09
wusewuwei
ľ³æ (СÓÐÃûÆø)
- ·ÒëEPI: 1
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3315
- Ìû×Ó: 170
- ÔÚÏß: 120.8Сʱ
- ³æºÅ: 276643
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
ǰÊÀ½ñÉú(½ð±Ò+50, ·ÒëEPI+1):Íò·Ö¸Ðл£¡£¡£¡ 2010-11-25 14:15:08
cfk580713(½ð±Ò+30):лл²ÎÓ룬ÐÁ¿àÁ˰¢ 2010-11-27 10:34:47
ǰÊÀ½ñÉú(½ð±Ò+50, ·ÒëEPI+1):Íò·Ö¸Ðл£¡£¡£¡ 2010-11-25 14:15:08
cfk580713(½ð±Ò+30):лл²ÎÓ룬ÐÁ¿àÁ˰¢ 2010-11-27 10:34:47
| ÒòΪENTPD5²»ÄÜÖ±½Ó½«ATPË®½âΪAMP£¬ÊµÑé½á¹û±íÃ÷ÔÚENTPD5ÖмÓÈëÔÓºÏMEFsÁËPTENµÄ S-100Ò²²»ÄÜÖ±½Ó½«ATPË®½âΪAMP£¬Òò´ËÎÒÃÇÈÏΪÔÚ½«ATPË®½âΪAMPµÄ¹ý³ÌÖУ¬S-100Öл¹ÐèÒªÆäËüÓ°ÏìÒò×Ó¡£ÕâЩÒò×Ó´æÔÚÓÚϸ°ûµÄPTEN̬£¬È´±»ÎÒÃǺöÊÓÁË¡£ÀýÈ磬µ±ÎÒÃǽ«´¿»¯¡¢ÖØ×éºóµÄENTPD5ºÍUMP¼ÓÈëµ½´Ó´óÁ¿×éÅàµÄHeLaϸ°ûÖÐ͸Îö³öÀ´µÄS-100ÖÐºó£¬ ATP¼´¿É±»Ë®½âΪAMP (ͼ4A, 1¨C6ÐÐ)¡£¸ÃÑо¿Ê¹µÃ·ÖÀëÕâЩӰÏìÒò×Ó±ä¼òµ¥ÁË£¬ÒòΪÅàÑøHeLaϸ°ûºÜÈÝÒס£ÎªÁËÈ·¶¨ÕâЩÒò×Ó£¬ÎÒÃǽ«HeLaϸ°ûS-100ÓÃÇíÖ¬ÌÇQ½øÐзֶÎ, ÊÕ¼¯Í¨ÖùÁ÷³öÒº£¬¼ÇΪQ-FL £»Óà 300 mM NaCl³åÖù£¬ÊÕ¼¯Á÷³öÒº£¬¼ÇΪQ-30.Á½²¿·Ö¾ù²»Äܽ«ATPË®½âΪAMP£¬µ«ÊÇQ-30ÔÚENTPD5 ºÍUMPµÄ´æÔÚÏ£¬Äܽ«ATPË®½âΪADP¡£µ±Q-FLºÍ Q-30¹²Í¬´æÔÚʱ£¬ATP¿ÉÒÔË®½âΪAMP(ͼ 4A, 18ÐÐ)¡£ÎÒÃÇ´ÓQ-30¶Î·ÖÀëµÃµ½ÁËÓ°ÏìÒò×Ó¡£½«Q-30ÒÀ´Îͨ¹ý4¸ùÉ«Æ×Öù£¬×îºóÔÙͨ¹ýÒ»¸ö΢ÐÍQÖù (×óͼ 4B)¡£ QÖùÓÃ40µ½120 mM NaCl½øÐÐÌݶÈÏ´ÍѲ¢ÊÕ¼¯£¬Ã¿²¿·ÖÓÃENTPD5¡¢UMP»ìºÏÒººÍ Q-FL¶Î½øÐÐÊÔÑé (ÓÒÏ£¬Í¼ 4B)¡£Ä¿±êÎï·åÖµ³öÏÖÔÚ8¨C10²¿·Ö. ¸Ã²¿·Öͨ¹ý SDS-PAGE silver staining, Á½µ°°×ÖÊÌõ´ø½Ó½ü marker 37 ºÍ20 kDa Óë»îÐÔ¼«Ïà¹Ø(ÓÒÉÏͼ4B)¡£¾ÖÊÆ×¼ø¶¨ÎªÈË UMP/CMP¼¤Ã¸-1 (CMPK1)¡£ Q-30heÖÐUMP/CMP¼¤Ã¸µÄ·¢ÏÖ ÎªÎÒÃǽâÊÍÁËΪʲôUMPÊÇATPø»îÐÔµÄÓ°ÏìÒò×ÓºÍENTPD5ÊÇÔõÑùºÍÕâÖÖø¹²Í¬×÷Óý«ATPË®½âΪADPµÄ¡£ÔÚÕâ¸ö·´Ó¦ÖУ¬ UMPÔÚCMPK1ºÍATP µÄ×÷ÓÃϽ«UDPÁ×Ëữ£¬²úÉúADP¡£ UDPÔÚENTPD5µÄ×÷ÓÃϱ»Ë®½âΪUMP£¬Íê³ÉATPµ½ADPµÄÒ»¸öÑ»·¡£ÔÚÕâ¸ö»ù´¡ÉÏ£¬ÎÒÃÇÍÆ²âµÚÈý¸öµ°°×Òò×Ó´æÔÚÓÚQ-FLÖУ¬²¢ÇÒÊÇ¿ÉÒÔ½«Á½¸öADPת»¯ÎªÒ»¸öATPºÍÒ»¸öAMµÄÏÙÜÕËἤø£¬Ê¹µÃPTENÁãϸ°ûÌáÈ¡ÎïÖÐÓÐ ATPת»¯ÎªAMPµÄ¹ý³Ì¡£ÎªÖ¤Ã÷¸ÃÍÆÂÛ£¬ÎÒÃǶÔQ-FL½øÐÐÁËÄý½º¹ýÂË£¬ ÊÕ¼¯ÂËÒºÔÚUMP¡¢´¿»¯¡¢ÖØ×éµÄENTPD5 ÒÔ¼°º¬ÓÐCMPK1µÄQ-30²¿·ÖµÄÌõ¼þϽøÐÐÊÔÑé¼ì²â ATPת»¯AMPµÄ»îÐÔ¡£ ATPת»¯ÎªAMP»îÐÔ·åÖµ¼¯ÖÐÓÚ 17-18 ¶Î (ÉÏͼ 4C)¡£½«ÕâÁ½¶ÎÓÃwesternÔÓ½»½øÐзÖÎö£¬ÓÃÏÙÜÕËἤø-1 (AK1)¿¹Ìå¼ì²â, ¼ì²âµ½µÄÌõ´øÓë»îÐÔ·åÍêÈ«Ïà¹Ø (ÏÂͼ 4C)¡£¾ÆäËûÉ«Æ×¼ì²âÏà¹ØÐÔÒÀÈ»´æÔÚ (ÎÞÊý¾Ý)¡£ÎÒÃÇÓÃϸ¾úµÃµ½ÖØ×éCMPK1ºÍAK1µ°°×²¢½«ËûÃǽøÐÐÁËͬÖÊ·ÖÀë (ͼ 4D£¬ 9-12ÐÐ)¡£ÓÃSDS-PAGE¼ì²âÏÔʾ£¬´¿»¯ºóµÄÖØ×é ENTPD5ÊǼÄÖ÷ϸ¾úϸ°ûµÄ3±¶£¬ÓÃPNGø F´¦Àí¹ýµÄÖØ×é ENTPD5µÄ±í´ïÊǼÄÖ÷µÄ2±¶£¬±íÃ÷ENTPD-5±»ÌÇ»ù»¯ÁË(ͼ4D£¬10-11ÐÐ)¡£ ÕâÐ©ÖØ×éµ°°×ÈÃÎÒÃÇÖØÏÖÁË ATPµ½AMPµÄË®½â¹ý³Ì¡£Ö»Óе±ÈýÖÖøºÍUMPͬʱ´æÔÚʱ£¬ ATPת»¯ÎªAMPµÄ¸ßЧ¹ý³Ì²ÅÄܽøÐÐ (ͼ4D, 1¨C8ÐÐ). |
6Â¥2010-11-24 19:38:37
wusewuwei
ľ³æ (СÓÐÃûÆø)
- ·ÒëEPI: 1
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3315
- Ìû×Ó: 170
- ÔÚÏß: 120.8Сʱ
- ³æºÅ: 276643
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
cfk580713(½ð±Ò+15):»¹ÓÐ15¸ö¹þ ºÇºÇ 2010-11-27 10:35:04
cfk580713(½ð±Ò+15):»¹ÓÐ15¸ö¹þ ºÇºÇ 2010-11-27 10:35:04
a°³Òª±Ò±Ò£¡ |
7Â¥2010-11-24 19:40:11













»Ø¸´´ËÂ¥
a°³Òª±Ò±Ò£¡